FDA Grants Rare Pediatric Disease Designation for Experimental Beta Thalassemia Drug
EDIT-301 is an investigational, gene editing medicine developed by Editas Medicine for the treatment of beta thalassemia. As recently reported in the Business Insider, EDIT-301 has just been granted the…